# T-cell lymphoma

The EU has approved 6 indications of 4 drugs in T-cell lymphoma. 2 of them need a biomarker result: ALK (1) and CD30 (1).

## Approved indications

### ALK fusion

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Crizotinib](https://oncolabels.com/drugs/crizotinib) (Xalkori) | ALK fusion | Monotherapy | 2nd line | Systemic ALCL only; Children and adolescents only; Relapsed or refractory; Age ≥ 1 to < 18 years |

### CD30-positive

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | CD30 CD30+ | Monotherapy | 2nd line | Cutaneous T-cell lymphoma only; After at least 1 prior systemic therapy |

### No biomarker required

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | None | + cyclophosphamide, doxorubicin and prednisone | 1st line | Systemic ALCL only |
| [Bexarotene](https://oncolabels.com/drugs/bexarotene) (Targretin) | None | Monotherapy | 2nd line, advanced | Cutaneous T-cell lymphoma only; After at least one systemic treatment; Skin manifestations |
| [Brentuximab vedotin](https://oncolabels.com/drugs/brentuximab-vedotin) (Adcetris) | None | Monotherapy | 2nd line | Systemic ALCL only; Relapsed or refractory disease |
| [Mogamulizumab](https://oncolabels.com/drugs/mogamulizumab) (Poteligeo) | None | Monotherapy | 2nd line | Cutaneous T-cell lymphoma only; After at least one prior systemic therapy |

## Label wording

- **Mogamulizumab** (Poteligeo), T-cell lymphoma, 2nd line: “POTELIGEO is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/poteligeo-epar-product-information_en.pdf)
- **Crizotinib** (Xalkori), T-cell lymphoma, 2nd line: “The treatment of paediatric patients (age ≥1 to <18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)” [SmPC](https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf)
- **Brentuximab vedotin** (Adcetris), T-cell lymphoma, 1st line: “ADCETRIS in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)
- **Brentuximab vedotin** (Adcetris), T-cell lymphoma, 2nd line: “ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory sALCL.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)
- **Brentuximab vedotin** (Adcetris), T-cell lymphoma, 2nd line: “ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (see section 5.1).” [SmPC](https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf)
- **Bexarotene** (Targretin), T-cell lymphoma, 2nd line, advanced: “Targretin is indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) in adult patients refractory to at least one systemic treatment.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/targretin-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/tumours/t-cell-lymphoma